Scientists Just Ended a 60-Year Debate About the Human Brain
A team led by Marta Paterlini at the Karolinska Institute in Sweden published their findings in Science. The study confirms that neurogenesis, the process of forming new brain cells, does in fact occur in adult humans—even into old age.
Researchers from the Karolinska Institute in Sweden found clear evidence of neural precursor cells and immature neurons in brains ranging from children to adults as old as 78.
That discovery finally settles a controversy that's lingered for more than 60 years.
In other animals, scientists have long known that the brain continues to make new neurons throughout life. But in humans, evidence was murky. Some previous studies identified young-looking brain cells in adults, but it wasn't clear if they were truly new or just slowly maturing cells leftover from early development.
To find out, researchers used advanced RNA sequencing to detect the molecular signatures of newly formed neurons and their precursors. First, they tested brain samples from children. Then, they searched for those same genetic markers in 19 postmortem brains ranging from 13 to 78 years old.
They found what they were looking for—proof of active neurogenesis in most of the adult samples, including in regions of the hippocampus, the part of the brain involved in memory and learning.
The findings open new doors for brain research, especially when it comes to neurodegenerative diseases and mental health conditions.
Disrupted neurogenesis has been linked to Alzheimer's disease and depression in mice, raising the possibility that therapies targeting this process could help prevent or treat these conditions in humans. Knowing these cells still exist in adulthood opens potential pathways for therapies that could stimulate brain regeneration.Scientists now believe other areas of the brain could also support neurogenesis, but that research is still ongoing.
This study doesn't just lay to rest a stubborn scientific question. It lays a foundation for new research into brain plasticity, aging, and mental illness. As scientists now have proof of active neurogenesis in adult humans, the next steps will target how to harness and enhance this natural capacity.
For now, the long-standing debate has finally been resolved. Adult brains don't just age—they adapt, and in some cases, they even grow.Scientists Just Ended a 60-Year Debate About the Human Brain first appeared on Men's Journal on Jul 10, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
I Gave Up Cardio After Weights – My Running And Lifting Has Never Been Better
Sometimes, it feels like science is on a mission to upset me. Not only does it turn out that upper body workouts (which I hate) might be key to better running, but apparently, cardio should be done after weights if you want to build muscle, pivotal to healthy ageing. Until about seven weeks ago, I was trying (and failing) to adopt the advice. I had previously been running before my strength training sessions every time I hit the gym – but the prospect of even a five-minute jog after Bulgarian split squats felt impossible. To be honest, though, the issues began long before that attempted change. Even when I was cramming cardio first in my hour-long, pre-work gym sessions, I didn't feel I was jogging for long enough to really improve my pace or endurance. And my lifts struggled, despite my (beloved) creatine supplementation. So, I stopped doing them in the same session altogether, in favour of separate sessions on the same day – and even though it doubles the amount of workouts on some days, I've been absolutely amazed by how much better I perform both at the squat rack and on the road. I split my running from my lifting altogether Rather than puffing desperately away on a treadmill after lifting (before giving up at the two-minute mark), I decided to try weightlifting before work and then jogging after it. Most days I only do one or the other, but I've been amazed to discover that even on the days when I do both, although it's double the load, I find both far easier – and it ends up taking about the same amount of time. My PBs for both have improved, too (not to mention the fact that my step count skyrocketed). According to Dr Suzanne Wylie, GP and medical adviser for IQdoctor, I'm not alone in my experience. 'It is quite common for people to notice better results when they separate strength training and cardiovascular exercise, rather than performing both in the same session,' she shared. 'By splitting your training into different times of day or alternating days entirely, you allow each type of workout to be performed when your body and nervous system are fresh, which can lead to greater strength gains, improved cardiovascular endurance, and less risk of injury.' Alex Kirkup-Lee, a personal trainer and writer at Gymshark, agrees. 'Ideally, you should split your cardio and weight training sessions, leaving four to six hours between workouts,' she explained, though she wouldn't recommend doing two intense sessions in a day. 'Balance your sessions with one higher intensity workout and one lower intensity, such as an interval run, and then light accessory work later, for example, core training... This allows for better recovery between each exercise type and maximises performance during both disciplines,' she recommended. So... is it ever OK to do cardio and weights in the same session? In short, yes. Kirkup-Lee explained that 'there might be a lot of reasons you want to do cardio and weights in one session, and it's important to note that it's also OK to do this'. Bear in mind, too, that I don't have kids and work from home – as the PT points out, 'many of us don't have time to train twice or even once a day, so it's best to not get too caught up in these finer details'. If you are going to try fitting both into a single session, either opt for a group class (which sometimes combines both) or, Kirkup-Lee said, go for weights before cardio. 'Lifting carries a higher risk of injury, and you don't want to pre-fatigue your muscles with cardio. Numerous studies have also proven that resistance training before cardio improves muscle strength and power,' she said. But if, like me, you find combining the two exhausting, try splitting them (ensuring you don't do two very hardcore sessions in one day) and see how you feel. For me, it's been life-changing. Related... I Tried 'Jeffing' And My Running Pace Skyrocketed I Swapped 10,000 Steps A Day For 30 Minutes Of 'Japanese Walking' – I've Never Been More Active I Tried 'Plogging,' The Eco-Friendly Running Trend – And I'll Never Do It Again
Yahoo
7 hours ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
The Verge
10 hours ago
- The Verge
SpaceX, a major federal contractor, 'has most likely paid little to no federal income taxes since its founding in 2002.'
Posted Aug 15, 2025 at 10:20 PM UTC Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates. Jay Peters Posts from this author will be added to your daily email digest and your homepage feed. See All by Jay Peters Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Science Posts from this topic will be added to your daily email digest and your homepage feed. See All Space Posts from this topic will be added to your daily email digest and your homepage feed. See All SpaceX
